🔥 Hot Deal
This Website for Sale — $300 + Domain & Free Setup • Current Revenue: $100/mo
Interested? Contact: davidjackup25@gmail.com

<sup>18</sup>F‑FAPI‑04 PET/CT imaging of fibroblast activating protein reveals myocardial injury beyond cancer staging.

← Research Home← More in this subcategory
Europe PMCPublished 2026Medicine & Clinical ResearchDisease Diagnosis & Prevention
Journal
Precision radiation oncology
Record source
Europe PMC Research Library

Abstract / Description

ObjectivesFluorine 18 (18F)-labeled fibroblast activation protein inhibitor-04 (denoted as FAPI-04) positron emission tomography/computed tomography (PET/CT) has showed excellent diagnostic performance for multiple solid tumors. However, its utility in characterizing myocardial injury has not yet been reported. In this study, the additional value of 18F-FAPI-04 PET/CT in assessing myocardial injury was evaluated in patients with cancer.MethodsMyocardial tracer uptake in 168 patients who underwent 18F-FAPI-04 PET/CT was analyzed retrospectively. Maximum and mean standard uptake values in the myocardium (SUVmax-myocardium and SUVmean-myocardium) and blood pool (SUVmax-BP and SUVmean-BP) were recorded. The ratio of SUVmax-myocardium to SUVmean-BP was denoted as the target-to-background ratio (TBR). Myocardial uptake higher than the background was visual uptake (n = 49), and uptake consistent with the background was no visual uptake (n = 119). Patients with abnormal uptake but without cardiovascular disease (CVD) were followed up.ResultsMyocardial uptake higher than the background was visual uptake (n = 49), and uptake consistent with the background was no visual uptake (n = 119). The prevalence of hypertension, diabetes mellitus (DM), CVD, and levels of cardiac troponin T and pro-BNP were higher in the visual uptake group (all p 
Read original research ↗Open DOI ↗